Cargando…
Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review
IMPORTANCE: For nearly a century, no generic form of insulin has been available in the United States. However, the first biosimilar insulin, Basaglar, was approved by the U.S. Food and Drug Administration in 2015, and subsequently Admelog and Lusduna in 2017. OBJECTIVE: To summarize the scientific e...
Autores principales: | Tieu, Carolyn, Lucas, Eleanor J., DePaola, Mindi, Rosman, Lori, Alexander, G. Caleb |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5905882/ https://www.ncbi.nlm.nih.gov/pubmed/29668697 http://dx.doi.org/10.1371/journal.pone.0195012 |
Ejemplares similares
-
Efficacy and immunogenicity of insulin biosimilar compared to their reference products: a systematic review and meta-analysis
por: Yang, Li-Jou, et al.
Publicado: (2022) -
Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis
por: Genovese, Mark C., et al.
Publicado: (2020) -
The efficacy and safety of the biosimilar product (Inflectra(®)) compared to the reference drug (Remicade(®)) in rescue therapy in adult patients with ulcerative colitis
por: Kaniewska, Magdalena, et al.
Publicado: (2017) -
Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-022 with reference trastuzumab
por: Alexeev, Sergey M., et al.
Publicado: (2020) -
Randomized double-blind clinical trial comparing safety and efficacy of the biosimilar BCD-021 with reference bevacizumab
por: Stroyakovskiy, Daniil L., et al.
Publicado: (2022)